Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.
- Presentation
Advanced Laboratory Testing in Dermatology: Next Steps and Practical Tips
Description
The presentation features Dr. Carl Sardi discussing advanced laboratory testing in dermatology, emphasizing the significance of precise diagnostics for rare conditions in both clinical and inpatient settings. He highlights how accurate diagnoses are crucial for effective treatment, mentioning laboratory developed tests (LDTs) and their ethical implications in relation to their utility and patient costs. Dr. Sardi illustrates his points through various case studies, addressing complex dermatological conditions such as ulcers potentially caused by xylazine, erythroderma leading to peripheral T-cell lymphoma, and perineoplastic autoimmune multi-organ syndrome due to a previous lymphoma treatment. He details diagnostic methods like MALDI-TOF mass spectrometry and 16S/18S RNA sequencing for identifying rare pathogens, stressing the importance of sequencing and referencing appropriate lab tests. Additionally, he talks about common testing pitfalls in commercial labs and shares insights into diagnostic panels available for various conditions like dermatitis herpetiformis and myositis. Each case illustrates the need for awareness of specific tests and the importance of collaboration with specialized labs, showcasing the challenges dermatologists face in ensuring comprehensive patient care.
View moreConclusions
- Precision testing is essential in dermatology to ensure accurate diagnoses and effective treatments, especially for obscure diseases.
- Laboratory developed tests present both utility and ethical challenges, particularly for rare conditions that lack extensive validation.
- Commercial laboratories often have limitations regarding the availability of specialized tests, which can impact patient care.
- Testing for xylazine exposure is crucial due to its prevalence in adulterated opioids and its association with severe skin ulcerations.
- Rapid diagnostic methods, such as MALDI-TOF mass spectrometry, are becoming increasingly important for the identification of pathogens in clinical settings.
- Flow cytometry, particularly for markers such as CD26, is vital for diagnosing conditions like Sézary syndrome, but many commercial labs do not offer this test.
- Clinical diagnostics for autoimmune blistering conditions require comprehensive testing and correlation with clinical findings, as false negatives can occur.
- New advances in genetic and serological testing can facilitate accurate diagnosis and treatment of dermatological conditions, improving patient outcomes.
- Lutz L, McFadden R, Xu L, et al. Wound characteristics among patients exposed to xylazine. JAMA Dermatol. 2025;161(1):75.
- Kwatra SG, Boozalis E, Pasieka H, Anhalt GJ. Decreased recognition of paraneoplastic pemphigus in patients previously treated with anti-CD 20 monoclonal antibodies. Br J Dermatol. 2019;180(5):1238-1239.
- Antiga E, Bech R, Maglie R, et al. S2k guidelines on the management of paraneoplastic pemphigus/paraneoplastic autoimmune multiorgan syndrome initiated by the European Academy of Dermatology and Venereology (eadv). Acad Dermatol Venereol. 2023;37(6):1118-1134.
- Paige W. Wolstencroft, BA; Livia Casciola-Rosen, PhD; David F. Fiorentino, MD, PhD Association Between Autoantibody Phenotype and Cutaneous Adverse Reactions to Hydroxychloroquine in Dermatomyositis. JAMA Dermatol.
- Inoue S, Okiyama N, Shobo M, et al. Diffuse erythema with 'angel wings' sign in Japanese patients with anti-small ubiquitin-like modifier activating enzyme antibody-associated dermatomyositis. Br J Dermatol. 2018;179(6):1414-1415.